Pfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral Treatment

發(fā)布時間： 2022-02-17 閱讀：467次

分享

February 12, 2022 -- Pfizer Inc. recently announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the conditional marketing authorization (CMA) of Pfizer’s PAXLOVID? (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.

In the U.S., PAXLOVID has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS CoV-2 viral testing, and who are at high-risk for progression to severe COVID-19, including hospitalization or death.

PAXLOVID is currently approved or authorized for emergency use in more than 10 countries across the globe.

The CHMP based its positive opinion on the data from the Phase 2/3 EPIC-HR trial. The data showed that PAXLOVID reduced the risk of hospitalization or death by 89% (within three days of symptom onset) and 88% (within five days of symptom onset) compared to placebo, with no deaths observed in the treatment group.